#1 Clinical Trials Search in Europe

HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B

Clinical trials are investigating HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B in adults with pulmonary arterial hypertension. These studies aim to evaluate its effect on pulmonary vascular resistance and other research outcomes, with a focus on safety and possible benefit in this patient group.

Table of Contents

Trial overview

The available trial data describe a Phase 2 study of HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B in adults with pulmonary arterial hypertension (PAH).[1] The brief study summary says the goal is to evaluate the effect of the study treatment on pulmonary vascular resistance (PVR).[1]

Who is being studied

This trial is for adult participants with PAH.[1] The source data do not give more detailed inclusion or exclusion rules, so the full list of who can join is not available here.

Trial design and treatment groups

The study is listed as an interventional trial, which means researchers assign a treatment and then measure the results.[1] The intervention list includes HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B and a placebo group, which helps compare outcomes fairly.[1] The intervention routes shown in the source are intravenous, subcutaneous, and intramuscular, but the data do not explain how these are used in the full study plan.[1]

What the study measures

The main outcome is the change from baseline in pulmonary vascular resistance (PVR).[1] Baseline means the starting measurement before treatment begins, and PVR is a measure of how hard it is for blood to flow through the lung blood vessels.[1] In simple terms, the study is checking whether the treatment changes the pressure or resistance in the lung circulation compared with the starting point.[1]

Trial status and size

The trial status is listed as Authorised.[1] The planned enrollment is 99 participants, which means up to 99 people are expected to be included in the study.[1]

What this means for patients

For people living with PAH, this study is part of early-to-mid stage clinical research looking for signs that HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B may affect lung blood flow measurements.[1] Because the trial is Phase 2, it is mainly focused on learning more about possible benefit while continuing to gather research information.[1] The source data do not report final results, so the trial should be seen as an ongoing or planned research effort rather than a proven treatment answer.[1]

Trial ID Phase Condition studied Status Enrollment
2024-514754-79-00 Phase 2 Pulmonary Arterial Hypertension (PAH) Authorised 99

FAQ

  • What condition is being studied in the trial? The trial is studying pulmonary arterial hypertension, also called PAH. This is a type of high blood pressure in the arteries of the lungs.
  • Who can take part in the study? The study is for adult participants. The trial data do not list more detailed entry rules in the source provided.
  • What phase is this clinical trial? This is a Phase 2 study. Phase 2 trials usually look more closely at whether a treatment may help and continue to monitor safety.
  • What is the main outcome being measured? The main outcome is the change from baseline in pulmonary vascular resistance, or PVR. Baseline means the starting point before treatment begins.
  • Is a placebo used in the study? Yes. The trial includes placebo to HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B. A placebo looks like the study treatment but does not contain the active study drug.

Ongoing Clinical Trials on HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B

  • A study to evaluate the effectiveness and safety of REGN13335 in adults with pulmonary arterial hypertension

    Recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Latvia Poland +1

Glossary

  • Pulmonary arterial hypertension (PAH): A disease with high blood pressure in the arteries that carry blood through the lungs. It can make the heart work harder.
  • Adult participants: People in the study who are 18 years old or older, or who meet the study's adult age rule.
  • Phase 2: A middle stage of clinical research. It usually checks early signs that a treatment may work and keeps studying safety.
  • Interventional study: A study in which researchers give one or more treatments and then measure the results.
  • Placebo: A treatment that looks like the study drug but has no active study medicine. It helps researchers compare results fairly.
  • Pulmonary vascular resistance (PVR): How hard it is for blood to flow through the blood vessels in the lungs. Higher resistance means the blood has more difficulty moving through.
  • Baseline: The starting measurement taken before treatment begins. Later results are compared with this starting point.
  • Enrollment: The number of people planned or allowed to join a study.
  • Authorised: The trial has been approved to start or continue by the relevant authority.
  • Intravenous: Given into a vein.
  • Subcutaneous: Given under the skin.
  • Intramuscular: Given into a muscle.

References

  1. https://clinicaltrials.gov/study/2024-514754-79-00